Abeona Therapeutics
ABEO
42 hedge funds and large institutions have $4.68M invested in Abeona Therapeutics in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 14 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
0.32% less ownership
Funds ownership: 0.89% → 0.57% (-0.32%)
22% less funds holding
Funds holding: 54 → 42 (-12)
55% less capital invested
Capital invested by funds: $10.5M → $4.68M (-$5.77M)
86% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$15.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$15K |
| 3 |
Renaissance Technologies
New York
|
+$14.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.98K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.97K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$1.58M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.01M |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$245K |
| 4 |
D.E. Shaw & Co
New York
|
-$163K |
| 5 |
Franklin Resources
San Mateo,
California
|
-$102K |
ABEO Hedge Fund Activity: Q2 2022 in Review
42 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q2 2022, worth a combined $4.68M — down 55% from $10.5M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ABEO and 2 opened new positions — a net loss of 12 holders — while 7 trimmed existing stakes and 11 added.
The largest buyer was State Street, adding an estimated $15.1K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $1.58M sold.
- 42 institutional investors held Abeona Therapeutics (ABEO) as of Q2 2022, down from 54 in Q1 2022.
- Funds reported $4.68M of Abeona Therapeutics stock for Q2 2022, down 55% quarter-over-quarter.
- 2 funds opened new Abeona Therapeutics positions in Q2 2022 and 14 closed out, a net change of -12 holders.
- The largest Abeona Therapeutics buyer in Q2 2022 was State Street, an estimated $15.1K added.
- The largest Abeona Therapeutics seller in Q2 2022 was AIGH Capital Management, an estimated $1.58M sold.
Based on aggregated 13F filings for Q2 2022.